myriad genetics glp-1 receptor agonist weight management diabetes treatments GLP1 Agonists—Effects beyond Obesity and Pharmacogenetics of Glucagon-like-peptide-1 receptor in

In clinical trials, people using GLP-1 drugs lost an average of about 10 pounds more than people using a placebo

A recent article by Paggers et al

This performance reflects unprecedented demand despite earlier supply constraints and sets the stage for pricing and reimbursement debates as the market matures

Here is a list of approved and pending new GLP-1 agonists class of medications that can help manage Type 2 diabetes and obesity.

For the 40% of American adults with obesity, glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, may offer hopebut the cost can put them out of reach for many patients

Genetics integration available: Add the Precision Peptide Genetic Test post-purchase ($99 one-time) for genetic insights across 14 health pathways